Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

By afschroeder • August 27, 2025

Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Aug 26. doi: 10.1038/s41591-025-03975-2. Epub ahead of print. Erratum for: Nat Med. 2025 Aug 14. doi: 10.1038/s41591-025-03875-5. PMID: 40858972.

Tags: Hematology/Oncology, Publications

Patient-reported discordance between care goals and treatment intent in advanced cancer

Shah MP, Wenger NS, Glaspy J, Hays RD, Sudore RL, Rahimi M, Gibbs L, Anand S, Tseng CH, Walling AM. Patient-reported discordance between care goals[...]

Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors

Anderson KG, Ribas A. Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors. J Immunother Cancer. 2025 Aug[...]

In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients

Mack PC, Crawford JM, Chang A, Yin A, Klein SL, Shea P, Hirsch FR, Zidar D, Simon V, Gleason C, McBride R, Cordon-Cardo C, VanOudenhove[...]